Phase I trial of weekly Docetaxel and daily Temozolomide in patients with metastatic disease

Investigational New Drugs

Volumn 26, Issue 6, 2008, Pages 553-559

  Tamaskar, I ^a   Mekhail, T ^a   Dreicer, R ^a   Olencki, T ^b   Roman, S ^a   Elson, P ^a   Bukowski, R M ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Docetaxel and Temozolomide; Phase I trial

Indexed keywords

DOCETAXEL; TEMOZOLOMIDE;

ADULT; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEAD CANCER; HUMAN; LUNG CANCER; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NECK CANCER; NEUTROPENIA; PETECHIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PURPURA; SOLID TUMOR; SURVIVAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; SURVIVAL RATE; TAXOIDS;

EID: 53749093223     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-008-9153-0     Document Type: Article

References (31)

1. MC Bissery D Guenard F Gueritte-Voegelein F Lavelle 1991 Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue Cancer Res 51 4845 4852
2. EK Rowinsky RC Donehower 1995 Paclitaxel (taxol) N Engl J Med 332 1004 1014
3. J-F Riou O Petitgenet C Combeau F Lavelle 1994 Cellular uptake and efflux of docetaxel (Taxotere®) and paclitaxel (Taxol®) in P388 cell line Proc Am Assoc Cancer Res 35 385
4. Taxotere package insert
5. ES Newlands GR Blackledge JA Slack GJ Rustin DB Smith NS Stuart 1992 Phase I trial of temozolomide (CCRG 81045: M and B 39831: NSC 362856) Br J Cancer 65 287 291
6. MF Stevens JA Hickman SP Langdon D Chubb L Vickers R Stone 1987 Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1, 2,3,5-tetrazin-4(3H)-one (CCRG 81045; M and B 39831), a novel drug with potential as an alternative to dacarbazine Cancer Res 47 5846 5852
7. ES Newlands MF Stevens SR Wedge RT Wheelhouse C Brock 1997 Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials Cancer Treat Rev 23 35 61
8. SD Baker M Wirth P Statkevich P Reidenberg K Alton SE Sartorius 1999 Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer Clin Cancer Res 5 309 317
9. M Patel C McCully K Godwin FM Balis 2003 Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates J Neurooncol 61 203 207
10. WK Yung MD Prados R Yaya-Tur SS Rosenfeld M Brada HS Friedman 1999 Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal brain tumor group J Clin Oncol 17 2762 2771
11. WK Yung RE Albright J Olson R Fredericks K Fink MD Prados 2000 A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse Br J Cancer 83 588 593
12. NM Bleehen ES Newlands SM Lee N Thatcher P Selby AH Calvert 1995 Cancer research campaign phase II trial of temozolomide in metastatic melanoma J Clin Oncol 13 910 913
13. MR Middleton JJ Grob N Aaronson G Fierlbeck W Tilgen S Seiter 2000 Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma J Clin Oncol 18 158 166
14. SR Wedge JK Porteous MG Glaser K Marcus ES Newlands 1997 In vitro evaluation of temozolomide combined with X-irradiation Anticancer Drugs 8 92 97
15. CS Adonizio JS Babb C Maiale C Huang J Donahue MM Millenson 2002 Temozolomide in non-small-cell lung cancer: preliminary results of a phase II trial in previously treated patients Clin Lung Cancer 3 254 258
16. C Christodoulou D Bafaloukos H Linardou G Aravantinos A Bamias M Carina 2005 Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a hellenic cooperative oncology group (HeCOG) phase II study J Neurooncol 71 61 65
17. D Bafaloukos H Gogas V Georgoulias E Briassoulis G Fountzilas E Samantas 2002 Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the hellenic cooperative oncology group J Clin Oncol 20 420 425
18. M Brada I Judson P Beale S Moore P Reidenberg P Statkevich 1999 Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies Br J Cancer 81 1022 1030
19. T Giannakakis N Ziras S Kakolyris D Mavroudis N Androulakis S Agelaki 2000 Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma: a multicentre phase I study Eur J Cancer 36 742 747
20. DT Rein CM Kurbacher M Breidenbach T Schondorf T Schmidt E Konig 2002 Weekly carboplatin and docetaxel for locally advanced primary and recurrent cervical cancer: a phase I study Gynecol Oncol 87 98 103
21. BT Hill RDH Whelan SA Shellard 1994 Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro Invest New Drugs 12 169 182
22. FA Shepherd J Dancey R Ramlau K Mattson R Gralla M O'Rourke 2000 Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2095 2103
23. M Di Maio F Perrone P Chiodini C Gallo C Camps W Schuette 2007 Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer J Clin Oncol 25 1377 1382
24. W Schuette S Nagel T Blankenburg C Lautenschlaeger K Hans EW Schmidt 2005 Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel J Clin Oncol 23 8389 8395
25. R Gervais A Ducolone JL Breton D Braun B Lebeau F Vaylet 2005 Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC) Ann Oncol 16 90 96
26. C Gridelli C Gallo M Di Maio E Barletta A Illiano P Maione 2004 A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. the DISTAL 01 study Br J Cancer 91 1996 2004
27. E Rivera JA Mejia BK Arun RB Adinin RS Walters A Brewster 2008 Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer Cancer 112 1455 1461
28. HJ Burstein J Manola J Younger LM Parker CA Bunnell R Scheib 2000 Docetaxel administered on a weekly basis for metastatic breast cancer J Clin Oncol 18 1212 1219
29. TM Loffler 1998 Is there a place for "dose-dense" weekly schedules of the taxoids? Semin Oncol 25 32 34
30. M Dhodapkar J Rubin JM Reid PA Burch HC Pitot JC Buckner 1997 Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer Clin Cancer Res 3 1093 1100
31. CS Brock ES Newlands SR Wedge M Bower H Evans I Colquhoun 1998 Phase I trial of temozolomide using an extended continuous oral schedule Cancer Res 58 4363 4367